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in the ICS group, the difference in mortality rate was not statis-
tically signiﬁcant (Hazard Ratio: 0.77 CI: 0.52; 1.15). However,
there was a signiﬁcant quality-of-life beneﬁt in favor of ICS.
CONCLUSIONS: Despite a lack of signiﬁcance in survival ben-
eﬁts, joint considerations of quality of life and survival indicate
that ICS could be considered potentially cost-effective. Imputa-
tion methods can be employed to address missing data issues
when the extent of missingness is not too extreme.
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OBJECTIVES: The study objective was to use administrative
claims to create episodes of acute respiratory care as a means of
better understanding the economic burden of acute treatment of
COPD. METHODS: Respiratory-related medical (ICD-9-CM
480.xx–519.xx) and pharmacy claims were extracted from a
managed care database for all patients 30 years of age or more
who were diagnosed with COPD (ICD-9-CM 491.xx, 492.xx,
and 496.xx) between 1997 and 2001. Acute respiratory-related
services were categorized as inpatient treatment, emergency
room (ER) treatment, or an ofﬁce visit combined with an antibi-
otic or oral steroid dispensed within three days of the visit.
Episodes of care were created by continuously combining acute
medical claims until a gap of 14 days or longer were found
between claims. Acute services after such a gap began a new
episode. Each patient was tracked longitudinally and all episodes
during the study period were included. Study measures included
service location, duration, and health plan payments (in 2002
$US). RESULTS: The average age of the 164,566 patients was
68 years, and 50% were male. Patients received more than
510,000 unique acute respiratory medical services; 37% were
inpatient, 22% ER, and 41% ofﬁce visits. These services were
combined to create 385,352 episodes (1.3 unique medical ser-
vices per episode), of which 45% involved inpatient care. The
average duration of episodes involving hospitalization was 10.6
days, with a mean payment of $12,661. These episodes lasted
2.6 days longer and payments were 12% more than individual
hospital stays. Approximately 10–15% of outpatient episodes
involved multiple ER or ofﬁce visits. Mean payments for ofﬁce
visit and ER episodes, including acute drug costs, were $231 and
$841, respectively. CONCLUSIONS: Combining individual
claims for acute respiratory services into episodes of care provide
a more comprehensive estimate of the costs of respiratory exac-
erbations for patients with COPD.
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OBJECTIVE: Chronic obstructive pulmonary disease (COPD) is
the fourth-leading cause of death in the United States and
accounts for about 14 billion dollars annually. This study
assesses the economic burden of COPD in a state health insur-
ance program in terms of medical resources and pharmacother-
apy from a payer perspective. METHODS: Outpatient, hospital
and emergency department (ED) claims with a primary ICD-9
code for chronic bronchitis (491.xx), emphysema (492.xx), and
chronic airways obstruction (496.xx) dated between July 1, 2001
and June 30, 2003 were extracted from the claims database of
a state health insurance program. Unique recipient identiﬁers
obtained from these claims were then used to extract COPD-
related prescription claims. Payer reimbursements were used to
calculate costs. Rates of use of maintenance medications was
assessed for the following therapeutic classes: 1) use of any
inhaled anti-inﬂammatory therapy (inhaled corticosteroids, cro-
molyn, nedocromil, and 2) use of “other” maintenance drugs
such as long-acting beta-agonists, leukotriene modiﬁers, anti-
cholinergics, and theophylline agents. RESULTS: Overall, COPD
prevalence was 52.2/1000 recipients. Of the 7165 recipients
identiﬁed with COPD, 11.8% (N = 848) received inhaled anti-
inﬂammatory drugs, and 19.4% (N = 1389) received “other”
maintenance medications for COPD. The hospitalization rate
was 7.9 hospitalizations/10,000 recipients, at a mean cost of
$1322 (SD = $1025) per visit per recipient (pvpr). The rates of
outpatient and ED use were 112 outpatient visits/1000 recipi-
ents, and 56 ED visits/10,000 recipients, respectively. The mean
cost pvpr for outpatient and ED use was $51 (SD = $72) and
$69 (SD = $80), respectively. The total COPD-related annual
average expenditures to the payer were $10,051,244 of which
prescription use accounted for 95%, followed by outpatient use
(4%), hospitalizations (0.7%), and ED use (0.3%). CONCLU-
SIONS: COPD exerted a signiﬁcant burden on the payer.
Although prescription use accounted for the most dollars, 
hospital use and costs were signiﬁcantly lower than national 
estimates.
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OBJECTIVE: Chronic respiratory illnesses such as asthma and
chronic obstructive pulmonary disease (COPD) not only impact
economic outcomes, but they also impact patients’ health-related
quality of life (HRQL). The objective of this study was to assess
the HRQL in patients with asthma and COPD. METHODS: All
employees receiving health beneﬁts through a state health insur-
ance program constituted the study population. Recipients
having medical claims with a primary ICD-9 code for asthma
(493.xx), chronic bronchitis (491.xx), emphysema (492.xx), or
chronic airways obstruction (496.xx) between July 1st, 2001 and
June 30th, 2003, were selected. These patients were classiﬁed as
having asthma-only, COPD-only, or having both asthma and
COPD, based on ICD9 codes. These patients were mailed the St.
George’s Respiratory Questionnaire (SGRQ), which has been
validated for measuring HRQL in patients with asthma as well
as COPD. The SGRQ consists of 3 subscales: symptoms, activ-
ity, and impacts, as well as a summary score, each ranging from
0 to 100, with higher scores indicating worse HRQL. T-tests and
ANOVAs were used to compare HRQL between the 3 groups.
RESULTS: Overall prevalence of chronic respiratory disease was
69.9/1000 recipients (asthma n = 1493; COPD n = 7165; both
n = 940). Overall survey response rate (RR) was 22.6% (asthma
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RR = 25.1%; COPD RR = 16%; both RR = 24%). The summary
HRQL score for recipients with both asthma and COPD was
43.8 (p < 0.0001), as compared to 36.4 for the COPD-only and
33.3 for the asthma-only groups. These differences persisted for
each of the 3 subscales, with recipients having both asthma and
COPD experiencing worse HRQL than those with asthma-only
or COPD-only. CONCLUSIONS: Increase in disease severity (as
indicated by the presence of both asthma and COPD as com-
pared to either disease by itself) was associated with statistically
as well as clinically signiﬁcant worsening of HRQL.
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OBJECTIVES: This study examined the persistence and adher-
ence for patients using latanoprost, travoprost, and bimatoprost
across multiple health plans over 12 months. METHODS: Glau-
coma patients were identiﬁed from an employer-based database
covering 1.8 million lives in 40 health plans. Patients with a glau-
coma medical claim and a pharmacy claim for latanoprost,
travoprost, or bimatoprost from September 31, 2001 through
March 31, 2002 were eligible for study entry. Continuous eligi-
bility was required 180 days prior to the index date, deﬁned as
the date of the ﬁrst prescription claim for an ophthalmic drug of
interest, with no evidence of ophthalmic drug use during that
time. These patients were deﬁned as “new therapy starts”. Per-
sistence at 12 months and number of days of adherence was
determined for new starts with at least 3 months of therapy fol-
lowing the index date. Due to potential inconsistencies with days
supply reporting at the pharmacy level, a clinical algorithm was
developed to compute days on therapy. RESULTS: At total of
3822 glaucoma patients were identiﬁed with at least one claim
for latanoprost, travoprost, or bimatoprost. Patients were on
average 73.1 years (SD = 10.1, range = 15–88) and 53.1%
female. A total of 2666 (69.8%) completed the ﬁrst three
months. A total of 70.1% were persistent with therapy at 12
months and were adherent 83.1% of the time. Using the quan-
tity dispensed and the number of days between reﬁlls yielded 8
days of therapy per 1-mL of ophthalmic solution. The mean
number of days on therapy for bimatoprost was signiﬁcantly
greater than latanoprost (p < 0.05). CONCLUSIONS: This ret-
rospective database analysis assessed persistence and adherence
for glaucoma patients using latanoprost, travoprost, and bimato-
prost for 12 months. Although most patients were persistent and
adherent to their therapy for at least 3 months and then at 12
months there may still be opportunities to improve persistence
and adherence with these important ophthalmic therapies.
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OBJECTIVE: It is a commonly known fact among physicians
that patients are non-adherent to medication regimens. In der-
matology, there has been little study into the issue of medication
non-adherence. This study examined trends in adherence behav-
ior (measured electronically) to topical medication regimen over
time in patients with psoriasis enrolled in a clinical study. Addi-
tionally, the association between adherence behavior and
changes in severity of psoriasis was explored. METHODS:
Twenty four subjects with psoriasis that were already enrolled in
an 8-week study with salicylic acid and topical tacrolimus oint-
ment combination therapy were given the salicylic acid in a
bottle with the Medication Event Monitoring System (MEMS)
cap. Electronic medication adherence was downloaded from the
cap to a computer at each follow up visit. The primary outcome
was the difference in the change from baseline in the disease
severity (sum score of erythema, scale and thickness scores).
RESULTS: Over the 8 week period the overall adherence rates
declined by 50% from 75.6% to 51%. A signiﬁcant correlation
was found between increased adherence and decreased disease
severity summary score in the ﬁrst week of treatment (Pearson’s
rho = -0.42, p = 0.02), after accounting for treatment effect. This
relationship did not persist after week 1. CONCLUSIONS: The
precipitous decrease in psoriasis medication adherence rates,
even in clinical study settings is cause for concern. Beneﬁts from
these medications may decrease as a result of decreased adher-
ence to prescribed regimens over time.
PES3
PRIOR AUTHORIZATION OF TOPICAL RETINOIDS NEEDED?
EVIDENCE FROM OUTPATIENT US NATIONAL PRACTICE
DATA
Balkrishnan R1, Shenolikar R1, Sansbury JC2, Feldman S2
1University of Texas School of Public Health, Houston,TX, USA;
2Wake Forest University School of Medicine, Winston-Salem, NC,
USA
OBJECTIVE: Fears of potentially costly use of topical retinoids
for cosmetic treatment of photodamaged skin has resulted in
many managed care organizations placing prior authorization
requirements on this class of medications. The purpose of this
investigation was to examine whether prescribing patterns of a
nationally representative sample of US physicians shed light on
potential inappropriate use of topical retinoids. METHODS: A
retrospective, cross-sectional study of data from the National
Ambulatory Medical Care Survey (1996–2000) was used to
determine the impact of patient diagnosis of acne on the proba-
bility of retinoid prescription were examined in weighted multi-
variate logistic regression models. RESULTS: Topical retinoids
were prescribed in 0.4% of the 3.67 billion visits for any diag-
nosis from 1996–2000, and in nearly 31% of the visits for 38.7
million visits for acne. The study found that there was negligi-
ble prescription of topical retinoids for non-acne related condi-
tions (Risk Ratio [RR] for topical retinoid prescription with acne
diagnosis: 58.8, 95% CI: 33.4, 103.7). This ﬁnding held when
individual retinoids (tretinoin and adapalene) were examined
separately. Clear age-related prescription trends were observed,
with signiﬁcant decrease in prescriptions beyond the teen years.
CONCLUSIONS: The data do not support a need for general
prior authorization of topical retinoids. Prior authorization
requirements for topical retinoids may not be necessary in young
patients, given the very small probability of non-acne related use.
In older patients, prior authorization, if needed at all, should
focus only on those topical retinoids for which there is evidence
of efﬁcacy in treatment of cosmetic photoaging.
